<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="70199"><DrugName>taselisib</DrugName><DrugNamesKey><Name id="43013568">taselisib</Name></DrugNamesKey><DrugSynonyms><Name><Value>GDC-0032</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RG-7604</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>taselisib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>RO-5537381</Value></Name><Name><Value>GDC-0326</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1282512-48-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19453">Genentech Inc</CompanyOriginator><CompaniesSecondary><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Company id="19446">Roche Holding AG</Company><Company id="19453">Genentech Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="70199" type="Drug"><TargetEntity id="729114" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="19453" type="Company"><TargetEntity id="4295912132" type="organizationId">Genentech Inc</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"></TargetEntity><TargetEntity id="D008228" type="MeSH"></TargetEntity><TargetEntity id="547" type="ORPHANET"></TargetEntity><TargetEntity id="-1008757452" type="omicsDisease"></TargetEntity><TargetEntity id="703" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1575" type="Action"><TargetEntity id="465" type="Mechanism">Phosphatidylinositol 3-Kinase (PI3K) Inhibitors</TargetEntity><TargetEntity id="3512" type="Mechanism">Inositol Phosphate Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01553" type="ciTarget"><TargetEntity id="59541" type="siTarget">Phosphatidylinositol 3-kinase (PI3K) (nonspecified subtype)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="49">Breast tumor</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="1575">Phosphoinositide 3-kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="898">Formulation powder</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2018-08-07T14:34:57.000Z</LastModificationDate><ChangeDateLast>2018-07-28T00:00:00.000Z</ChangeDateLast><AddedDate>2011-02-23T13:31:58.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt;, a subsidiary of &lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt;,  was developing taselisib (GDC-0032, RG-7604), a beta-isoform sparing phosphoinositide 3-kinase (PI3K) inhibitor, for the potential oral treatment of solid tumors, including breast cancer [&lt;ulink linkID="1609862" linkType="Reference"&gt;1609862&lt;/ulink&gt;]. &lt;ulink linkID="15414" linkType="Company"&gt;Chugai Pharmaceutical&lt;/ulink&gt; was also involved in the phase I development of this drug in Japan  [&lt;ulink linkID="1720891" linkType="Reference"&gt;1720891&lt;/ulink&gt;], [&lt;ulink linkID="1721071" linkType="Reference"&gt;1721071&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2015, a phase III trial (SANDPIPER) was initiated in ER+/HER2-/PIK3CA-mutant  metastatic breast cancer  [&lt;ulink linkID="1628327" linkType="Reference"&gt;1628327&lt;/ulink&gt;].  In September 2014, a phase II trial (&lt;ulink linkID="214085" linkType="Protocol"&gt;&lt;/ulink&gt;LORELEI) of neoadjuvant &lt;ulink linkID="2784" linkType="Drug"&gt;&lt;/ulink&gt;taselisib was initiated for ER+/HER2- primary breast cancer [&lt;ulink linkID="1721585" linkType="Reference"&gt;1721585&lt;/ulink&gt;]; in September 2017, data were presented [&lt;ulink linkID="1962901" linkType="Reference"&gt;1962901&lt;/ulink&gt;], [&lt;ulink linkID="1962606" linkType="Reference"&gt;1962606&lt;/ulink&gt;]. In March 2011, a phase I/II trial in solid tumors, non-Hodgkin's lymphoma and metastatic HR-positive breast cancer began   [&lt;ulink linkID="1170377" linkType="Reference"&gt;1170377&lt;/ulink&gt;]; in March 2017, data were presented [&lt;ulink linkID="1909417" linkType="Reference"&gt;1909417&lt;/ulink&gt;].    In December 2015,  a phase Ib study in Japanese HR+ locally advanced or  metastatic breast cancer patients was ongoing [&lt;ulink linkID="1720891" linkType="Reference"&gt;1720891&lt;/ulink&gt;], [&lt;ulink linkID="1721071" linkType="Reference"&gt;1721071&lt;/ulink&gt;]; in March 2017, data were presented [&lt;ulink linkID="1909417" linkType="Reference"&gt;1909417&lt;/ulink&gt;]. In April 2018, filings for  taselisib plus fulvestrant in PIK3CA mutant ER+/HER2- metastatic breast cancer were expected in 2018 [&lt;ulink linkID="1896883" linkType="Reference"&gt;1896883&lt;/ulink&gt;]. In April 2018, EU and US filings for neoadjuvant taselisib plus letrozole in ER-positive/HER2-negative breast cancer were expected in 2021 or later [&lt;ulink linkID="2027862" linkType="Reference"&gt;2027862&lt;/ulink&gt;]. In June 2018, Roche announced that it was terminating development of taselisib after data from the phase III SANDPIPER trial showed only modest efficacy and a risk of serious side effects; the company also stated that it did not plan to continue with development in other types of cancer [&lt;ulink linkID="2057733" linkType="Reference"&gt;2057733&lt;/ulink&gt;]. In July 2018, Chugai reported that it had also decided to discontinue development of taselisib for solid tumors, having considered the results of studies conducted by Roche [&lt;ulink linkID="2057705" linkType="Reference"&gt;2057705&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was previously developing the drug for the potential treatment of second-line squamous non-small-cell lung cancer (NSCLC). In June 2014, a phase II/III trial (Lung-MAP) in second-line squamous NSCLC was initiated [&lt;ulink linkID="1581138" linkType="Reference"&gt;1581138&lt;/ulink&gt;]. In February 2017, it was reported that the phase II portion of the study did not meet pre-specified criteria for further development and that taselisib had been discontinued for this indication [&lt;ulink linkID="1896883" linkType="Reference"&gt;1896883&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The drug has patent coverage until September 2030 in the US, Europe and Japan [&lt;ulink linkID="PA6397369" linkType="Patent"&gt;US-08242104&lt;/ulink&gt;], [&lt;ulink linkID="PA7052549" linkType="Patent"&gt;EP-02483278&lt;/ulink&gt;], [&lt;ulink linkID="PA7290992" linkType="Patent"&gt;JP-05540101&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In April 2015, regulatory submission for ER-positive HER2-negative breast cancer as a neoadjuvant treatment was planned for 2018  [&lt;ulink linkID="1653537" linkType="Reference"&gt;1653537&lt;/ulink&gt;].  In April 2018, EU and US filings for neoadjuvant taselisib plus letrozole in ER-positive/HER2-negative breast cancer were expected in 2021 or later [&lt;ulink linkID="2027862" linkType="Reference"&gt;2027862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, filing for HER2-negative ER-positive metastatic breast cancer was expected  in 2017 or later [&lt;ulink linkID="1653537" linkType="Reference"&gt;1653537&lt;/ulink&gt;]. In February 2017, filings for taselisib plus fulvestrant in PIK3CA mutant ER+/HER2- metastatic breast cancer were expected in 2018 [&lt;ulink linkID="1896883" linkType="Reference"&gt;1896883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In April 2015, regulatory submission for second-line  squamous NSCLC was expected in 2018 or later [&lt;ulink linkID="1653537" linkType="Reference"&gt;1653537&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In January 2015, a randomized, double-blinded, placebo-controlled, parallel assigned, phase III trial (&lt;ulink linkID="220103" linkType="Protocol"&gt;NCT02340221&lt;/ulink&gt;; GO29058, 2014-003185-25; SANDPIPER) began in  Canada, the US, Australia, Europe, Asia, Turkey, Mexico and South America in postmenopausal women (expected n = 600) with ER+/HER2-/PIK3CA-mutant  locally advanced or metastatic breast cancer, to compare the efficacy and safety of taselisib plus &lt;ulink linkID="3313" linkType="Drug"&gt;fulvestrant&lt;/ulink&gt; versus placebo plus fulvestrant. At that time, the trial was expected to complete in June 2018 [&lt;ulink linkID="1628327" linkType="Reference"&gt;1628327&lt;/ulink&gt;]. In October 2016, recruitment was ongoing with more than  200 patients enrolled  [&lt;ulink linkID="1805985" linkType="Reference"&gt;1805985&lt;/ulink&gt;]. In June 2018, data were presented at the 54th ASCO Annual Meeting in Chicago, IL. The trial met its primary endpoint of improved PFS (7.4 versus 5.4 months for placebo) for a Hazard ratio of 0.7. Benefit was observed across all subgroups, including prior therapy and site of metastasis. Geographic location results differed: n Asia (7.3 versus 3.7 months; HR = 0.38) and in the US, EU, Canada and Australia (7.7 versus 4.5 months; HR = 0.57), and rest of the world saw no PFS improvement. ORR was 28 versus 16% for placebo, and the clinical benefit rate was 51.5 and 37.3%, respectively. Overall survival data were immature. In patients who did not harbor PI3K mutations, some benefit was seen (PFS = 4 versus 5.6 months). Treatment duration was longer in the treatment arm, although those patients who did discontinue in the treatment arm did so more for tolerability reasons than in the placebo arm. Taselisib showed grade 3 or above adverse events in 49.5% of subjects, compared to 16.4% for fulvestrant alone. The most common grade 3 or above adverse events were diarrhea (11.5 versus 0.9%), hyperglycemia (10.8 versus 0.5%), rash (3.8 versus 0%) and stomatitis (3.6 versus 0%) [&lt;ulink linkID="2039309" linkType="Reference"&gt;2039309&lt;/ulink&gt;], [&lt;ulink linkID="2041023" linkType="Reference"&gt;2041023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2014, an investigator-led, prospective, randomized, open-label, single-group-assignment, phase I/II trial (&lt;ulink linkID="215284" linkType="Protocol"&gt;NCT02285179&lt;/ulink&gt;; POSEIDON; M14POS) was initiated in Europe to assess the safety and efficacy of taselisib in combination with &lt;ulink linkID="44314" linkType="Drug"&gt;tamoxifen&lt;/ulink&gt; compared with tamoxifen alone in patients (expected n = 32) with hormone receptor positive, HER2-negative metastatic breast cancer who had progressed after prior endocrine treatment. The primary endpoint was the MTD assessed in the first 28 days of treatment. The trial was expected to complete in July 2019 [&lt;ulink linkID="1701042" linkType="Reference"&gt;1701042&lt;/ulink&gt;], [&lt;ulink linkID="1700696" linkType="Reference"&gt;1700696&lt;/ulink&gt;]. In October 2015, the dose-escalation phase I portion of the trial had been completed; at that time, the randomized phase II portion was  to commence in 2015 and complete by the end of 2017 with approximately 300 patients participating  [&lt;ulink linkID="1700696" linkType="Reference"&gt;1700696&lt;/ulink&gt;]. In June 2016, phase Ib results were presented at the 52nd ASCO meeting in Chicago, IL. Patients were treated with tamoxifen + taselisib (2 mg, qd) 21 days/ 7 days off (cohort 1; n = 6), tamoxifen + taselisib (4 mg, qd) 21 days/ 7 days off (cohort 2; n = 13) and tamoxifen + taselisib (4 mg, qd continuous; cohort 3, n = 11). DLTs or grade &amp;gt; 5 AEs were not observed. The recommended phase II dose of taselisib in combination with tamoxifen was determined to be 4 mg on a daily continuous schedule. Taselisib + tamoxifen demonstrated antitumor activity in PI3KCA mutant and wild-type tumors. Pharmacokinetic analysis demonstrated that significant drug-drug interactions were not anticipated when taselisib was used in combination with tamoxifen [&lt;ulink linkID="1767519" linkType="Reference"&gt;1767519&lt;/ulink&gt;]. In December 2016, it was reported that in the phase II part of the study, patients would randomized (1:1) to receive tamoxifen (continuous) with taselisib or placebo until disease progression, unacceptable toxicity or patient decision. The primary endpoint was investigator assessed progression-free survival [&lt;ulink linkID="1885203" linkType="Reference"&gt;1885203&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, a randomized, double-blind, phase II trial (&lt;ulink linkID="214085" linkType="Protocol"&gt;NCT02273973&lt;/ulink&gt;; GO28888; LORELEI) of neoadjuvant &lt;ulink linkID="2784" linkType="Drug"&gt;letrozole&lt;/ulink&gt; + taselisib versus letrozole + placebo in postmenopausal women (estimated n = 330) with ER+/HER2- primary breast cancer was initiated in the US, Australia, Europe, South America, South Korea and Mexico.  At that time, the trial was expected to complete in July 2017 [&lt;ulink linkID="1611008" linkType="Reference"&gt;1611008&lt;/ulink&gt;]. By June 2015, 54 of  330 patients had been enrolled and  enrollment was ongoing [&lt;ulink linkID="1721585" linkType="Reference"&gt;1721585&lt;/ulink&gt;].  In September 2017, clinical data were presented at the ESMO 2017 Congress in Madrid, Spain. Addition of taselisib to letrozole increased the objective response rate from 38 to 56.2% in the PIK3CA MUT subset (n = 152; odds ratio [OR] 2.03, p = 0.033) and from 39.3 to 50% in all randomized patients (OR 1.55, p = 0.049); thereby the study met its primary endpoint. Overall or in the PIK3CA MUT subset, no significant difference was observed for pathologic complete response rate (co-primary endpoint) was observed. Gastrointestinal disorders (7.8%), infections (4.8%), and skin/subcutaneous tissue disorders (4.8%) were the most common grade 3 to 4 adverse events in the taselisib arm [&lt;ulink linkID="1962901" linkType="Reference"&gt;1962901&lt;/ulink&gt;], [&lt;ulink linkID="1962606" linkType="Reference"&gt;1962606&lt;/ulink&gt;]. In December 2017, further data were presented at the 40th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. Compared to placebo in all randomized patients and in the PIK3CA mutant cohort, taselisib showed significantly higher ORR, assessed by breast US. In all randomized patients, complete cell cycle arrest (CCCA) at week 3 was numerically higher with taselisib than to placebo, (49.6 versus 38.5%, respectively), and in PIK3CA MT (60.9 versus 47.5%, respectively) [&lt;ulink linkID="1989759" linkType="Reference"&gt;1989759&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2017, clinical data from a phase I study (&lt;ulink linkID="224540" linkType="Protocol"&gt;NCT02390427&lt;/ulink&gt;) were presented at the 53rd ASCO meeting in Chicago, IL. Patients (n = 28) received escalated dose of taselisib (2 or 4 mg) + trastuzumab. The most common grade 3+ adverse events reported were thrombocytopenia, diarrhea, vomiting, increase in lipase and hyperglycemia. Confirmed responses were observed in 24 patients (complete response, partial response and stable disease in 4, 29 and 50%, respectively). The median progression free survival was 7.6 months [&lt;ulink linkID="1931911" linkType="Reference"&gt;1931911&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, data were presented at the 37th Annual San Antonio Breast Cancer Symposium in San Antonio, TX, from a phase Ib study of taselisib in combination with letrozole in patients with hormone receptor-positive advanced breast cancer. Data from 28 patients showed no DLTs at either the 6 mg (n = 20) or 9 mg (n = 8) dose levels. The most common grade 3 and above AE was diarrhea, which was experienced by 4 patients. No drug-drug interaction was observed and preliminary data assessment by FDG-PET showed that 11 out of 18 patients had a partial metabolic response. Data from two patients, one each for 6- and a 9-mg taselisib + letrozole, showed confirmed partial response at cycle 4 [&lt;ulink linkID="1616586" linkType="Reference"&gt;1616586&lt;/ulink&gt;], [&lt;ulink linkID="1620686" linkType="Reference"&gt;1620686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013,  data from a clinical study were presented at the 2013 Frontiers in Medicinal Chemistry Annual meeting in San Francisco, CA. In HER2-negative MBC patients with the PIK3CA mutation H1047R, 2 cycles of taselisib therapy resulted in confirmed partial response [&lt;ulink linkID="1442414" linkType="Reference"&gt;1442414&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, an open-label, dose-escalation, multicenter, phase I study (&lt;ulink linkID="134380" linkType="Protocol"&gt;NCT01862081&lt;/ulink&gt;; GO27802) was started in the US to assess the safety, tolerability, and pharmacokinetics of taselisib administered in combination with either &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; or with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; in patients with HER2-negative locally recurrent or metastatic breast cancer (estimated n = 65). At that time, the study was expected to complete by January 2016 [&lt;ulink linkID="1439660" linkType="Reference"&gt;1439660&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In June 2014, Southwest Oncology Group began an open  label,  randomized, parallel assignment,   phase II/III efficacy study (&lt;ulink linkID="193506" linkType="Protocol"&gt;NCT02154490&lt;/ulink&gt;, S1400, NCI-2014-00627, S1400E, S1400A, S1400C, S1400D, S1400B, S1400, S1400, U10CA180888, Lung-MAP), that linked  genomically screened participants to a new targeted therapy protocol. In the study, patients (expected n = 10,000), were to receive &lt;ulink linkID="81193" linkType="Drug"&gt;MEDI-4736&lt;/ulink&gt;, docetaxel (&lt;ulink linkID="2953" linkType="Drug"&gt;Taxotere&lt;/ulink&gt;), taselisib,   &lt;ulink linkID="10271" linkType="Drug"&gt;palbociclib&lt;/ulink&gt;, &lt;ulink linkID="64468" linkType="Drug"&gt;AZD-4547&lt;/ulink&gt;, &lt;ulink linkID="53074" linkType="Drug"&gt;rilotumumab&lt;/ulink&gt; or  &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt; in monotherapy or in combination at sites in the US. At that time, the estimated primary completion date was June 2022 [&lt;ulink linkID="1580367" linkType="Reference"&gt;1580367&lt;/ulink&gt;], [&lt;ulink linkID="1580872" linkType="Reference"&gt;1580872&lt;/ulink&gt;], [&lt;ulink linkID="1581138" linkType="Reference"&gt;1581138&lt;/ulink&gt;]. In February 2017, it was reported that the phase II portion of the study did not meet pre-specified criteria for further development and that taselisib had been discontinued for this indication [&lt;ulink linkID="1896883" linkType="Reference"&gt;1896883&lt;/ulink&gt;]. In June 2017, further clinical data from a phase II study (LUNG-MAP sub-study SWOG S1400B; &lt;ulink linkID="262150" linkType="Protocol"&gt;NCT02785913&lt;/ulink&gt;) were presented at the 53rd ASCO meeting in Chicago, IL. Study S1400B failed to meet its primary endpoint and toxicities were manageable [&lt;ulink linkID="1931934" linkType="Reference"&gt;1931934&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid  and hematological malignancies and early-stage trials&lt;/subtitle&gt;In June 2017, clinical data from phase I were presented at the 53rd ASCO meeting in Chicago, IL. Patients (n = 33) received taselisib (4 or 2 mg, qd) + palbociclib (100 or 125 mg, qd) 3 weeks on and 1 week off, followed by dose expansion. Mucositis, hyperglycemia and fatigue were the DLTs reported.The combination of taselisib and palbociclib were well-tolerated [&lt;ulink linkID="1932021" linkType="Reference"&gt;1932021&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, clinical data from an open-label, single-dose, four-part, crossover, phase I study which evaluated the impact of formulation and food on taselisib in 74 healthy subjects were presented at the 117th ASCPT Annual Meeting in San Diego, CA. were randomized to receive taselisib (3 mg tablet) in fasting and fed conditions, or taselisib (3 mg, powder-in-capsule (PIC)), prototype tablet (2 mg) or forumulated capsule. Following a single dose of taselisib, the prototype tablet exhibited 1.5 fold-higher exposure and 2-fold higher Cmax when compared with the original PIC. A small reduction in Cmax was noted following administration of taselisib 3 mg in fed condition when compared with fasting condition. The 2-mg prototype tablet showed similar exposure to the original 3-mg capsule [&lt;ulink linkID="1743422" linkType="Reference"&gt;1743422&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2015,   data were presented at the 38th Annual San Antonio Breast Cancer Symposium in San Antonio, TX from a phase Ia/Ib study (JO29196) evaluating the safety, tolerability and pharmacokinetics of taselisib as a monotherapy and in combination with fulvestrant in Japanese patients.  In phase Ia, advanced solid tumor patients (n = 9; PIK3CA  mutant n = 2) received taselisib tablet monotherapy (2, 4 or 6 mg qd). No DLT was observed at any dose. Partial response was seen in one patient on taselisib 4 mg dose who had a PIK3CA mutant breast tumor, and stable disease was seen in four patients. Cmax and AUC values were dose-proportional. Pharmacokinetics in Japanese patients were consistent with North American and European patients. In the ongoing phase Ib, hormone receptor-positive locally advanced or metastatic breast cancer patients (n = 3) received taselisib (2 or 4 mg qd) in combination with fulvestrant (500 mg at a time). No DLT or grade &amp;gt;/= 3 event was observed.  Evaluation of tolerability of the 4 mg dose in combination with fulvestrant was ongoing [&lt;ulink linkID="1720891" linkType="Reference"&gt;1720891&lt;/ulink&gt;], [&lt;ulink linkID="1721071" linkType="Reference"&gt;1721071&lt;/ulink&gt;]. In July 2016, further clinical data were presented at the Japanese Society of Medical Oncology 2016 Annual Meeting in Kobe, Japan. The grade &amp;gt;/= 3 adverse reactions reported in phase Ia study were rash, neutropenia, anemia and lung infection. In the 4 mg taselisib group, two patients achieved partial response (a patient had PIK3CA mutant breast cancer). The grade &amp;gt;/= 3 adverse reactions observed in phase Ib study were colitis, gingivitis, increase in ALT and dermatitis acneiform. In the combination therapy group, a patient achieved partial response [&lt;ulink linkID="1894675" linkType="Reference"&gt;1894675&lt;/ulink&gt;]. In March 2017, retrospective analysis data about the effect of acid reducing agents (ARAs; such as proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs)) on the pharmacokinetics of taselisib were presented at the 118th ASCPT Annual Meeting in Washington DC. A patient who received a single dose of taselisib (4 mg, qd) tablet with PPI had low taselisib exposure, and this taselisib low exposure was not observed in the same patient with multiple taselisib doses and discontinuation of PPI [&lt;ulink linkID="1909417" linkType="Reference"&gt;1909417&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2015, clinical data were presented from a phase I, two-period, fixed sequence, two-arm drug interaction study which evaluated the pharmacokinetic interaction between  taselisib  and &lt;ulink linkID="51474" linkType="Drug"&gt;rifampin&lt;/ulink&gt; or &lt;ulink linkID="3411" linkType="Drug"&gt;itraconazole&lt;/ulink&gt; in healthy subjects at the 116th ASCPT Annual Meeting in New Orleans, LA.											 Subjects received taselisib (3 mg) followed by rifampin (600 mg, qd)  then  taselisib was co-administered with rifampin or  itraconazole  (200 mg, qd). Concomitant administration of rifampin decreased the Cmax, AUC and mean apparent t1/2 values of taselisib, whereas the respective values were increased approximately following concomitant administration of itraconazole [&lt;ulink linkID="1638990" linkType="Reference"&gt;1638990&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, clinical data were presented from a phase I, open-label, two-arm study which evaluated the absolute bioavailability and mass balance of taselisib  in healthy subjects at the 116th ASCPT Annual Meeting in New Orleans, LA.											In arm A, subjects (n = 8) received a single dose of taselisib (3 mg powdered-capsule formulation, po) followed 4 h later by a single dose of [14C]- taselisib (3 microg, iv dose). In arm B, subjects (n = 6) received a single dose of [14C]- taselisib (3 mg capsule, po). Taselisib had absolute bioavailability of 57.4% and 84.2% of taselisib was recovered as unchanged drug in urine and feces [&lt;ulink linkID="1638994" linkType="Reference"&gt;1638994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, a clinical trial application of oral tablet formulation was filed in China by Roche, presumably for solid tumors [&lt;ulink linkID="1644169" linkType="Reference"&gt;1644169&lt;/ulink&gt;]; in March  2016,  reivew of the application was concluded though the outcome was not published yet  [&lt;ulink linkID="1766605" linkType="Reference"&gt;1766605&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, an open-label, multicenter, dose-escalation, phase I/II trial (&lt;ulink linkID="74778" linkType="Protocol"&gt;NCT01296555&lt;/ulink&gt;; PMT4979g; GO00886) to assess the safety, tolerability and pharmacokinetics of  taselisib in patients (expected n = 122) with locally advanced or metastatic solid tumors (phase I) or non-hodgkin's lymphoma and in combination with endocrine therapy (&lt;ulink linkID="2784" linkType="Drug"&gt;letrozole&lt;/ulink&gt; or fulvestrant) in patients with locally advanced or metastatic HR+ breast cancer (phases I and II) began in the US, Canada and Europe [&lt;ulink linkID="1170377" linkType="Reference"&gt;1170377&lt;/ulink&gt;]. In April 2013, data were presented at the 104th AACR meeting in Washington DC. Daily doses showed dose-linear and time-dependent pharmacokinetics. Half-life was approximately 40 h, with a Tmax of 2 h following single doses. Safety, tolerability and preliminary antitumor activity data recommended a phase II daily dose of 9 mg. Common adverse events potentially related to the drug at grade 3 or above included diarrhea, fatigue and hyperglycemia. DLTs were grade 3 acute renal failure (n = 1 12 mg qd dose) and a grade 4 hyperglycemia and grade 3 fatigue (n = 1 each 16-mg qd dose). Metabolic partial response was seen in 12 out of 17 patients. Out of 12 patients with PIK3CA mutant solid tumors, 5 and 4 showed partial response (PR) and stable disease (SD), respectively: patients with mutant breast cancer showed 4 PR and 2 SD out of 6 individuals [&lt;ulink linkID="1399949" linkType="Reference"&gt;1399949&lt;/ulink&gt;], [&lt;ulink linkID="1400654" linkType="Reference"&gt;1400654&lt;/ulink&gt;]. In September 2013, data from 57 patients were presented at the 2013 European Cancer Congress in Amsterdam, the Netherlands.  Metabolic partial response was seen in 18 of 33 patients [&lt;ulink linkID="1481378" linkType="Reference"&gt;1481378&lt;/ulink&gt;]. By October 2013, the trial was also recruiting in Canada [&lt;ulink linkID="1170377" linkType="Reference"&gt;1170377&lt;/ulink&gt;]. In October 2013, data from the study presented at the 25th International AACR-NCI-EORTC Symposium in Boston, MA, showed no drug-to-drug interaction with midazolam  [&lt;ulink linkID="1490290" linkType="Reference"&gt;1490290&lt;/ulink&gt;], [&lt;ulink linkID="1490236" linkType="Reference"&gt;1490236&lt;/ulink&gt;]. In December 2013, data were presented at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, TX. In the phase Ib study, patients (n = 17) with metastatic breast cancer received taselisib  (6 to 9 mg qd) in combination with fulvestrant (500 mg q4w). A total of 8 of 11 patients achieved a metabolic partial response and confirmed partial responses by RECIST were reported at both doses of taselisib, including in patients with prior fulvestrant treatment [&lt;ulink linkID="1512919" linkType="Reference"&gt;1512919&lt;/ulink&gt;]. In April 2014, biomarker data were presented at AACR 2014. By June 2014, recruitment had completed {n = 320) [&lt;ulink linkID="1609862" linkType="Reference"&gt;1609862&lt;/ulink&gt;]. In November  2015, the study was expected to complete in September 2019  [&lt;ulink linkID="1170377" linkType="Reference"&gt;1170377&lt;/ulink&gt;].  In June 2016, further clinical data from 60 patients were presented at the 52nd ASCO meeting in Chicago, IL. Of 44 patients with measurable disease at baseline, confirmed partial responses were noted in 38.5, 10.5 and 25%, respectively, and clinical benefit rate was noted in 38.5, 15.8 and 41.7% of patients, respectively, in patients with PIK3CA mutated tumors, wild-type PIK3CA tumors, unknown PIK3CA tumor mutation status [&lt;ulink linkID="1767648" linkType="Reference"&gt;1767648&lt;/ulink&gt;]. In December 2016, further clinical data were presented at the 39th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. In the central analysis, best confirmed response and clinical benefit ratio (primary endpoint) was observed in patients with PIK3Ca mutant tumors (38.5% each) compared with patients with patients with PIK3CA-wild type tumors (10.5 and 15.8%, respectively) [&lt;ulink linkID="1885304" linkType="Reference"&gt;1885304&lt;/ulink&gt;]. In March 2017, retrospective analysis data about the effect of ARAs such as PPIs and H2RAs on the pharmacokinetics of taselisib were presented at the 118th ASCPT Annual Meeting in Washington DC. The dose-normalized steady-state taselisib concentrations were similar between patients who used (n = 52) and did not use ARAs (n = 119), and also these concentrations appeared to be not impacted by the capsule versus tablet formulation [&lt;ulink linkID="1909417" linkType="Reference"&gt;1909417&lt;/ulink&gt;]. In April 2018, further data were presented at 109th AACR Annual Meeting in Chicago, IL. In patients treated with taselisib, the most common adverse events (AEs, overall) including diarrhea, nausea, hyperglycemia and fatigue were reported by &amp;gt;/= 30% of patients. In patients treated with taselisib, confirmed response rates were 8.9% and clinical benefit rates (confirmed response or without disease progression for &amp;gt;/= 6 months) were 12.3% [&lt;ulink linkID="2025846" linkType="Reference"&gt;2025846&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2018, in vitro data were presented at the 255th ACS National Meeting and Exposition in New Orleans, LA. Taselisib spared inhibition of PI3Kbeta compared with PI3Kalpha [&lt;ulink linkID="2013362" linkType="Reference"&gt;2013362&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, proof of concept data from in vitro and in vivo studies were presented at the 108th AACR Annual Meeting in Washington DC. After treatment with GDC-0032 alone or in combination with everolimus, apoptosis was induced in BT474, MDA-MB-453 and HCC1954 cells. In BC mouse xenografts harboring PIK3CA mutation and HER2 amplification, GDC-0032 exhibited high activity in reducing established tumor growth [&lt;ulink linkID="1914342" linkType="Reference"&gt;1914342&lt;/ulink&gt;]. Further in vitro data were presented at the same conference. At 3 days post treatment with taselisib, between PIK3CA wild type and mutant breast cancer cell lines, a 26.8-fold difference was observed for IC50 values (p = 0.0007). PI3K pathway was suppressed with induced apoptosis in HER2ampPIK3CA-mutant cell lines treated with taselisib (200 nM), while in HER2ampPIK3CA-wild type cell lines PI3K pathway suppression and apoptosis was driven by HER2 inhibition [&lt;ulink linkID="1914329" linkType="Reference"&gt;1914329&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, preclinical data were presented at the 39th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. Taselisib blocked the kinase signaling and induced down regulation of mutant p110 alpha protein in a dose dependent and time dependent manner. In PIK3CA mutant xenografts, the MTD dose of taselisib conferred superior anti-tumor activity [&lt;ulink linkID="1885205" linkType="Reference"&gt;1885205&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. Over 550 cell lines derived from 13 of the main tissue types, response to taselisib was observed in a small percentage of all tumor types, which had a strong correlation with PIK3CA mutations. Taselisib IC50 values were &amp;lt; 0.5 microM for majority of head and neck squamous cell cancer (HNSCC) indicating that HNSCC cell lines might in particular demonstrated susceptibility to taselisib [&lt;ulink linkID="1755687" linkType="Reference"&gt;1755687&lt;/ulink&gt;]. Further data were also presented at the same conference. Taselisib demonstrated improved activity when compared with pan-Class I PI3K inhibitor in PI3Ka mutant cancer cells. Taselisib produced greater apoptosis in PIK3CA mutant cells (which had superior pathway suppression during the time of feedback), induced tumor regression in PIK3CA mutant xenograft mice model and uniquely degraded mutant PI3Ka [&lt;ulink linkID="1755691" linkType="Reference"&gt;1755691&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2015, a series of benzoxazepin derivatives had been synthesized and evaluated as PI3K inhibitors. The most potent compounds, GDC-0326 displayed high affinity with Ki value of 0.2 nM against PI3K-alpha. The compound showed anti-proliferative activity with EC50 values of 0.1 and 2.2 microM against MCF7-neo/HER2 and PC3 human cancer cell lines [&lt;ulink linkID="1910528" linkType="Reference"&gt;1910528&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In  April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA. Taselisib exhibited enhanced potency towards P13Ka mutant cancer cells when compared with pan-P13K inhibitors, maintained pathway suppression and induced apoptosis in cells with RTK-stimulated pathway activation [&lt;ulink linkID="1649590" linkType="Reference"&gt;1649590&lt;/ulink&gt;]. Further preclinical data were also presented at the same conference showing that   a decrease in plasma PIK3CA allele frequency was noted from 3.05% in the pretreatment sample to 0.14% in the study discontinuation sample obtained from a patient who experienced a sustained clinical partial response to taselisib along with fulvestrant [&lt;ulink linkID="1649435" linkType="Reference"&gt;1649435&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, preclinical data were presented at the 248th ACS meeting in San Francisco, CA.							In mouse xenograft model, taselisib  had high unbound drug exposure and robust in vivo anti-tumor activity [&lt;ulink linkID="1581612" linkType="Reference"&gt;1581612&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, in San Antonio, TX. In combination with letrozole, taselisib  decreased cell viability and increased apoptosis compared with either agent alone. taselisib  induced apoptosis in cell lines and xenograft models of mutated PIK3CA [&lt;ulink linkID="1512981" linkType="Reference"&gt;1512981&lt;/ulink&gt;]. Further data presented at the conference showed that taselisib  increased tumor regression in several breast cancer models when used in combination with taxanes, endocrine therapies and anti-HER2 therapies [&lt;ulink linkID="1512969" linkType="Reference"&gt;1512969&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, preclinical data were published. Data demonstrated that a set of imidazobenzoxazepin compounds lowered intrinsic clearance, improved the unbound drug exposure with suppressed tumor growth at low dose levels in a mouse xenograft model  [&lt;ulink linkID="1427369" linkType="Reference"&gt;1427369&lt;/ulink&gt;], [&lt;ulink linkID="1427019" linkType="Reference"&gt;1427019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 245th ACS Meeting in New Orleans, LA. Of all the compounds tested, taselisib showed &amp;gt;50-fold selectivity of alpha over beta [&lt;ulink linkID="1391792" linkType="Reference"&gt;1391792&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2013, data were presented at the 104th AACR meeting in Washington DC. Taselisib enhanced the efficacy of endocrine therapies in breast cancer models and had a strong inhibitory effect in breast cancer cell lines including in the submicromolar range for PI3K mutant lines. The drug was effective in combination with &lt;ulink linkID="2784" linkType="Drug"&gt;letrozole&lt;/ulink&gt; in vitro, showing increased apoptosis. Further pharmacokinetic data showed clearance in mouse, rat, dog, and cynomolgus monkey of 2.7, 1.8, 10, and 4.1 ml/min/kg, respectively, and oral bioavailability in mouse and rat of 100 and 99% [&lt;ulink linkID="1400671" linkType="Reference"&gt;1400671&lt;/ulink&gt;], [&lt;ulink linkID="1399957" linkType="Reference"&gt;1399957&lt;/ulink&gt;], [&lt;ulink linkID="1400654" linkType="Reference"&gt;1400654&lt;/ulink&gt;]. In June 2013, further data were presented at the 2013 Frontiers in Medicinal Chemistry Annual meeting in San Francisco, CA. In HCC1954 breast cancer xenografts with PI3K-alpha H1047R mutation, GDC-0032 (25 mg/kg qd po) treatment for 21 days resulted in greater tumor growth inhibition when compared with 150 mg/kg po qd GDC-0941 (138 versus 90%) and vehicle [&lt;ulink linkID="1442414" linkType="Reference"&gt;1442414&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2012, preclinical data were presented for taselisib at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, in San Antonio, TX. The activity of fulvestrant was enhanced when combined with taselisib in MCF-7 xenografts. Furthermore, the efficacy of tamoxifen was enhanced in vivo when combined with the compound [&lt;ulink linkID="1352578" linkType="Reference"&gt;1352578&lt;/ulink&gt;]. In April 2013, similar data were presented at the 104th AACR meeting in Washington DC. In the MCF-7  xenograft model there was 91% tumor growth inhibition with the combination [&lt;ulink linkID="1400671" linkType="Reference"&gt;1400671&lt;/ulink&gt;], [&lt;ulink linkID="1400654" linkType="Reference"&gt;1400654&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2017-02-01T00:00:00.000Z</StatusDate><Source id="1896883" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-07-26T00:00:00.000Z</StatusDate><Source id="2057705" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2018-07-26T00:00:00.000Z</StatusDate><Source id="2057705" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2018-06-02T00:00:00.000Z</StatusDate><Source id="2057733" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2014-06-26T00:00:00.000Z</StatusDate><Source id="1581138" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1611008" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1611008" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1611008" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1611008" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1611008" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2014-09-30T00:00:00.000Z</StatusDate><Source id="1611008" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1628327" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1628327" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1628327" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1628327" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1628327" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1628327" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1628327" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2011-03-31T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-12-10T00:00:00.000Z</StatusDate><Source id="1720891" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2015-12-10T00:00:00.000Z</StatusDate><Source id="1720891" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2011-02-14T00:00:00.000Z</StatusDate><Source id="1170377" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01553"><Name>Phosphoinositide 3-kinase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N</Smiles><Smiles>C[C@@H](C(=O)N)Oc1ccc-2c(c1)OCCn3c2nc(c3)c4ncnn4C(C)C</Smiles></StructureSmiles><Deals><Deal id="158947" title="Genentech and Chugai Pharmaceutical to develop taselisib for solid tumor and breast cancer     "/></Deals><PatentFamilies><PatentFamily id="2650619" number="WO-2013182668" title="Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer"/><PatentFamily id="2798369" number="WO-2014140073" title="Process for making benzoxazepin compounds"/><PatentFamily id="3030627" number="WO-2015136016" title="Therapeutic combinations with estrogen receptor modulators"/><PatentFamily id="3091726" number="WO-2015191986" title="Methods of treating and preventing cancer drug resistance"/><PatentFamily id="3387438" number="WO-2016151063" title="Combinations of a phosphoinositide 3-kinase inhibitor compound and a CDK4/6 inhibitor compound for the treatment of cancer"/><PatentFamily id="3490112" number="WO-2017001362" title="Methods of treatment with taselisib"/><PatentFamily id="663067" number="WO-2011036280" title="Benzoxazepin PI3K inhibitor compounds and methods of use"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>